Streetbeat News

Products Services

IE

Ivanhoe Electric Inc. (NYSE:IE) and Saudi Arabian Mining Company Ma'aden have initiated joint venture exploration activities in Saudi Arabia. The 50/50 joint venture aims to explore approximately 48,500 km2 of land on the Arabian Shield, provided by Ma'aden, to tap into the region's significant mineral potential.

Portfolio Pulse from Charles Gross

November 29, 2023 | 12:20 pm

HROW

Harrow Health, Inc. has successfully completed the transfer of the New Drug Application (NDA) for Triesence, a synthetic corticosteroid used to treat various ocular inflammatory conditions, to its own portfolio.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:14 pm

QURE

The FDA has approved uniQure's Investigational New Drug (IND) application for AMT-191, a gene therapy for Fabry Disease. This clearance allows uniQure to proceed with clinical trials, potentially leading to a new treatment option for patients with this genetic disorder.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:13 pm

BCDA

BioCardia, Inc. has announced that following a recent consultation with Japan's Pharmaceuticals and Medical Devices Agency (PMDA), the PMDA indicated that data from outside Japan may be sufficient for the approval of BioCardia's CardiAMP autologous cell therapy. This development suggests that BioCardia may not need to conduct additional clinical trials within Japan, potentially accelerating the approval process for CardiAMP in the Japanese market.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:10 pm

KZIA

Kazia Therapeutics has signed a non-binding letter of intent to develop and commercialize its pharmaceutical product containing Paxalisib for uses beyond oncology. This move could potentially open new markets and applications for the drug, which is currently focused on treating brain cancer. The details of the agreement, including financial terms and specific non-oncology applications, have not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:06 pm

BCRX

BioCryst Pharmaceuticals has announced that its drug ORLADEYO (berotralstat) has been approved by Argentina's National Administration of Drugs, Foods, and Medical Devices (ANMAT). This approval allows for the treatment of hereditary angioedema (HAE) in patients in Argentina.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:06 pm

GBTC

MSTR

Andrew Tate compared Michael Saylor's responsible business practices at MicroStrategy with Sam Bankman-Fried's fraudulent activities at FTX. Tate highlighted Saylor's net-benefit approach to business, contrasting it with Bankman-Fried's 0-benefit strategy, which led to his conviction on fraud charges. Tate also discussed the potential SEC approval of a Bitcoin ETF, mentioning several contenders for the ETF including Grayscale, Ark/21 Shares, Bitwise, BlackRock, VanEck, WisdomTree, Valkyrie, Invesco Galaxy, and Fidelity Wise Origin.

Portfolio Pulse from Mehab Qureshi

November 29, 2023 | 12:04 pm

EVGO

EVgo Inc. (NASDAQ:EVGO) is expanding its partnership with regional grocery retailer Meijer to install new fast charging stations in Ohio. These stations will feature up to six stalls with high-power 350kW chargers, enhancing the EV charging infrastructure in the Midwest and providing EV drivers with quick charging options.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:03 pm

SABS

SABSW

SAB Biotherapeutics has announced its plans to file IND and CTA with the U.S. FDA and EMA in 2024 to progress its SAB-142 into a Phase 2b clinical study.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:01 pm

GBIO

MRNA

Generation Bio has announced its intention to continue developing ctLNP for immune cells in collaboration with Moderna. Additionally, Generation Bio plans to develop iqDNA for its lead Hemophilia A and other programs.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:01 pm